SION Stock — Sionna Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.28

Market cap

$148.3M

Cash

$268.2M

Enterprise value

-$119.9M

Balance sheet

Cash	$268.2M
Debt	$0.0M
Net cash	$268.2M
Enterprise value	-$119.9M
Basic shares	45.2M shares
Fully diluted shares	53.3M shares
Fully diluted market cap	$174.9M
Cash per share	$5.94
Quarterly burn	$22.2M
Cash runway	12.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

45.2M

Pre-funded warrants

0.0M

Options

7.3M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.8M

FDSO

53.3M

Cap table as of 2026-06-30.

Price history

Loading SION daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

SION-719

Phase 2 · Active Modality: small molecule NBD1 stabilizer

Target NBD1

Indications

cystic fibrosis (Stage not disclosed)

Catalysts

— None

Status note Phase 2a proof-of-concept trial (PreciSION CF) evaluating SION-719 as an add-on to standard of care (Trikafta) in CF patients; enrollment completed in April 2026. Positive topline data from two Phase 1 trials in healthy volunteers announced June 2025.

SION-451

Phase 1 · Active Modality: small molecule NBD1 stabilizer

Target NBD1

Indications

cystic fibrosis (Stage not disclosed)

Catalysts

— None

Status note Phase 1 dual-combination trial in healthy volunteers with SION-2222 and SION-109 initiated in August 2025 to inform selection of a proprietary dual combination for further development.

SION-2222

Phase 1 · Active Modality: CFTR modulator

Target CFTR

Indications

cystic fibrosis (Stage not disclosed)

Status note Complementary CFTR modulator being evaluated in dual combinations with SION-451.

SION-109

Phase 1 · Active Modality: CFTR modulator

Target CFTR

Indications

cystic fibrosis (Stage not disclosed)

Status note Complementary CFTR modulator being evaluated in dual combinations with SION-451.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	9,905,045	no change	3.79%	2026-08-14
OrbiMed Advisors	2,555,877	-974,825	2.13%	2026-08-14
Perceptive Advisors	905,000	+246,561	0.62%	2026-08-14
Deerfield Management	680,916	-289,674	0.31%	2026-08-14
Casdin Capital	400,000	+400,000	0.88%	2026-08-14
Baker Bros. Advisors	400,000	no change	0.09%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SION — Sionna Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

SION — Sionna Therapeutics Inc.